A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

August 31, 2008

Conditions

LeukemiaMyelodysplastic Syndromes

Interventions

DRUG

MGCD0103

MGCD0103 oral dose given 2 times per week.

Trial Locations (4)

Columbia University Medical Center, New York

Lee Moffitt Cancer Center, Tampa

University of Chicago Medical Center, Chicago

Sir Mortimer Davis Jewish General Hospital, Montreal